Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status

FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

(2015) Koichi Azuma et al.   Oncotarget

EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation

(2014) M. Wang et al.   CANCER RESEARCH

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells

(2011) N Ioannou et al.   BRITISH JOURNAL OF CANCER

EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

(2011) V. Poindessous et al.   CLINICAL CANCER RESEARCH

Mitotic catastrophe: a mechanism for avoiding genomic instability

(2011) Ilio Vitale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status

(2010) R. J. Kimple et al.   CLINICAL CANCER RESEARCH

ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway

(2010) Mahmoud Toulany et al.   RADIOTHERAPY AND ONCOLOGY

Chemoradiotherapy in the Management of Locally Advanced Pancreatic Carcinoma: A Qualitative Systematic Review

(2009) Florence Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Antagonists in Cancer Treatment

(2008) Fortunato Ciardiello et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression

(2008) Liang-Yi Hung et al.   NUCLEIC ACIDS RESEARCH

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

(2008) D Li et al.   ONCOGENE